Effects of dapagliflozin on serum uric acid levels in hospitalized type 2 diabetic patients with inadequate glycemic control: a randomized controlled trial

References

• GrassiDFerriLDesideriGChronic hyperuricemia, uric acid deposit and cardiovascular riskCurr Pharm Des201319132432243823173592
   PubMed Web of Science ®Google Scholar
• BobulescuIAMoeOWRenal transport of uric acid: evolving concepts and uncertaintiesAdv Chronic Kidney Dis201219635837123089270
   PubMed Web of Science ®Google Scholar
• MutluayRDegerSMBahadirEDurmazAOCitilRSindelSUric acid is an important predictor for hypertensive early atherosclerosisAdv Ther201229327628622392103
   PubMed Web of Science ®Google Scholar
• FukuiMTanakaMShiraishiESerum uric acid is associated with microalbuminuria and subclinical atherosclerosis in men with type 2 diabetes mellitusMetabolism200857562562918442624
   PubMed Web of Science ®Google Scholar
• LoefflerLFNavas-AcienABradyTMMillerER3rdFadrowskiJJUric acid level and elevated blood pressure in US adolescents: National Health and Nutrition Examination Survey, 1999–2006Hypertension201259481181722353609
   PubMed Web of Science ®Google Scholar
• KimSYGuevaraJPKimKMChoiHKHeitjanDFAlbertDAHyperuricemia and coronary heart disease: a systematic review and meta-analysisArthritis Care Res (Hoboken)201062217018020191515
   PubMed Web of Science ®Google Scholar
• HanTMengXShanRTemporal relationship between hyperuricemia and obesity, and its association with future risk of type 2 diabetesInt J Obes (Lond)20184271336134429717279
   PubMed Web of Science ®Google Scholar
• BholeVChoiJWKimSWde veraMChoiHSerum uric acid levels and the risk of type 2 diabetes: a prospective studyAm J Med20101231095796120920699
   PubMed Web of Science ®Google Scholar
• ChienKLChenMFHsuHCPlasma uric acid and the risk of type 2 diabetes in a Chinese communityClin Chem200854231031618089655
   PubMed Web of Science ®Google Scholar
• KrishnanEPandyaBJChungLHaririADabbousOHyperuricemia in young adults and risk of insulin resistance, prediabetes, and diabetes: a 15-year follow-up studyAm J Epidemiol2012176210811622753829
   PubMed Web of Science ®Google Scholar
• JuraschekSPMcAdams-DemarcoMMillerERTemporal relationship between uric acid concentration and risk of diabetes in a community-based study populationAm J Epidemiol2014179668469124418684
   PubMed Web of Science ®Google Scholar
• MadianovIVBalabolkinMIMarkovDSMarkovaTNMain causes of hyperuricemia in diabetes mellitusTer Arkh20007225558
   PubMed Web of Science ®Google Scholar
• YuSChenYHouXSerum uric acid levels and diabetic peripheral neuropathy in type 2 diabetes: a systematic review and meta-analysisMol Neurobiol20165321045105125579387
   PubMed Web of Science ®Google Scholar
• DengZGuYHouXAssociation between uric acid, cancer incidence and mortality in patients with type 2 diabetes: Shanghai diabetes registry studyDiabetes Metab Res Rev201632332533226409171
   PubMed Web of Science ®Google Scholar
• ValbusaFBertoliniLBonapaceSRelation of elevated serum uric acid levels to incidence of atrial fibrillation in patients with type 2 diabetes mellitusAm J Cardiol2013112449950423672990
   PubMed Web of Science ®Google Scholar
• LiQYangZLuBSerum uric acid level and its association with metabolic syndrome and carotid atherosclerosis in patients with type 2 diabetesCardiovasc Diabetol2011107221816063
   PubMed Web of Science ®Google Scholar
• KalraSSodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacologyDiabetes Ther20145235536625424969
   PubMed Web of Science ®Google Scholar
• Abdul-GhaniMADeFronzoRADapagliflozin for the treatment of type 2 diabetesExpert Opin Pharmacother201314121695170323800130
   PubMed Web of Science ®Google Scholar
• StrojekKYoonKHHrubaVElzeMLangkildeAMParikhSEffect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trialDiabetes Obes Metab2011131092893821672123
   PubMed Web of Science ®Google Scholar
• FerranniniERamosSJSalsaliATangWListJFDapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trialDiabetes Care201033102217222420566676
   PubMed Web of Science ®Google Scholar
• BaileyCJGrossJLPietersABastienAListJFEffect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trialLancet201037597332223223320609968
   PubMed Web of Science ®Google Scholar
• KirkRDiabetes: efficacy of dapagliflozin associated with renal functionNat Rev Endocrinol2013912688
   Google Scholar
• WildingJPWooVSolerNGLong-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trialAnn Intern Med2012156640541522431673
   PubMed Web of Science ®Google Scholar
• NauckMADel PratoSMeierJJDapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trialDiabetes Care20113492015202221816980
   PubMed Web of Science ®Google Scholar
• BaileyCJGrossJLHennickenDIqbalNMansfieldTAListJFDapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trialBMC Med2013114323425012
   PubMed Web of Science ®Google Scholar
• JabbourSAHardyESuggJParikhSStudy 10 GroupDapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled studyDiabetes Care201437374075024144654
   PubMed Web of Science ®Google Scholar
• ListJFWooVMoralesETangWFiedorekFTSodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetesDiabetes Care200932465065719114612
   PubMed Web of Science ®Google Scholar
• KatoKSuzukiKAokiCThe effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trialExpert Opin Pharmacother201718874375128426260
   PubMed Web of Science ®Google Scholar
• AhmadiehHAzarSEffects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitusDiabetes Technol Ther201719950751228749169
   PubMed Web of Science ®Google Scholar
• ZhaoYXuLTianDEffects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trialsDiabetes Obes Metab201820245846228846182
   PubMed Web of Science ®Google Scholar
• ScorsoneASauraGFleresMEfficacy and renal safety of dapagliflozin in patients with type 2 diabetes mellitus also receiving metformin: a real-life experienceJ Diabetes Res20188501418529854825
   PubMed Web of Science ®Google Scholar
• Schumm-DraegerPMBurgessLKorányiLHrubaVHamer-MaanssonJEde BruinTWTwice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trialDiabetes Obes Metab2015171425125200570
   PubMed Web of Science ®Google Scholar
• WuBZhengHGuJEffects of sodium-glucose cotransporter 2 inhibitors in addition to insulin therapy on cardiovascular risk factors in type 2 diabetes patients: a meta-analysis of randomized controlled trialsJ Diabetes Investig Epub2018619
   Web of Science ®Google Scholar
• ArakiEOnishiYAsanoMEfficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: results of the interim analysis of 16-week double-blind treatment periodJ Diabetes Investig201674555564
   Web of Science ®Google Scholar
• ChinoYSamukawaYSakaiSSGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuriaBiopharm Drug Dispos201435739140425044127
   PubMed Web of Science ®Google Scholar
• McGillJBThe SGLT2 inhibitor empagliflozin for the treatment of type 2 diabetes mellitus: a bench to bedside reviewDiabetes Ther201451436324729157
   PubMed Web of Science ®Google Scholar
• LiSSannaSMaschioAThe GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohortsPLoS Genet2007311e19417997608
   PubMed Web of Science ®Google Scholar
• CookCBEliasBKongableGLPotterDJShepherdKMMcMahonDDiabetes and hyperglycemia quality improvement efforts in hospitals in the United States: current status, practice variation, and barriers to implementationEndocr Pract201016221923020061279
   PubMed Web of Science ®Google Scholar
• ClementSBraithwaiteSSMageeMFManagement of diabetes and hyperglycemia in hospitalsDiabetes Care200427255359114747243
   PubMed Web of Science ®Google Scholar